Meredith M. Regan, ScD
Office phone: 617-632-2471
Preferred contact method: email
Area of Research
Statistical Methods in Cancer Research
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Dr. Regan is Associate Professor of Medicine, Harvard Medical School. She earned her doctorate in Biostatistics from Harvard School of Public Health. After completing a fellowship at the Biometrics Center at Beth Israel Deaconess Medical Center, she joined the faculty at BIDMC, and in 2003 joined the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology. Dr. Regan was appointed Group Statistician for the International Breast Cancer Study Group (IBCSG) in 2009 and is a member of the IBCSG Scientific Executive Committee.
ResearchStatistical Methods in Cancer Research
Dr. Regan’s research focuses on clinical and translational research in breast and genitourinary cancers. She is Director of the Biostatistics and Computational Biology Core of the DF/HCC Prostate Cancer SPORE, past Core Director of the DF/HCC Kidney Cancer SPORE, and Core Co-Director of the DF/HCC Breast Cancer SPORE. In a new initiative led by Dr. Christopher Sweeney, the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) Working Group is conducting an individual patient data meta-analysis to evaluate surrogate endpoints for overall survival in randomized clinical trials for localized prostate cancer treatment.
Dr. Regan is Group Statistician for the International Breast Cancer Study Group (IBCSG). She is the lead statistician for the international randomized clinical trials SOFT and TEXT evaluating the adjuvant endocrine therapy in premenopausal women with early-stage breast cancer. With IBCSG colleagues, her translational research focuses on features of the disease or patient that inform selection of endocrine therapy for individual patients.
Dr. Regan’s statistical research focuses on long-term analysis of randomized clinical trials with selective crossover, in which patients on the control arm are provided the opportunity to take the experimental treatment after first dissemination of the trial’s results; the work is motivated by the international BIG 1-98 and HERA trials adjuvant early breast cancer trials.